Vernice Bates, MD
Neurology · Amherst, NYNPI 1801958202
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,342 of the $9,061 with a category attached, or 70.0%. 36 manufacturers reported payments, led by AbbVie at 29.3% of the total. Reporting peaked in 2021 at $3,500 and has fallen 85.1% since, to $521 in 2025.
Across 310 payments — averaging $29.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$1K
- Avanir Pharmaceuticals, Inc.$804
- Pfizer$459
- Lilly USA, LLC$401
- Otsuka America Pharmaceutical, Inc.$372
- plus $3K from 30 others
Across 2 payments — averaging $465.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$930
Across 7 payments — averaging $45,288 each. An ownership or investment interest held by the physician or an immediate family member.
- Neurology Practice Consortium GPO, LLC$317K
What the payments were for
- Consulting fees$2,37026%
- Food & beverage$6,34270%
- Education$3494%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $2,656 |
| Teva Pharmaceuticals USA, Inc. | 44 | $1,043 |
| Avanir Pharmaceuticals, Inc. | 38 | $804 |
| Pfizer | 25 | $459 |
| Lilly USA, LLC | 18 | $401 |
| Otsuka America Pharmaceutical, Inc. | 20 | $372 |
| UCB, Inc. | 9 | $369 |
| Novartis | 14 | $306 |
| Eisai Inc. | 13 | $295 |
| Acadia Pharmaceuticals Inc | 10 | $293 |
| Lundbeck LLC | 10 | $229 |
| Adamas Pharmaceuticals, Inc. | 10 | $223 |
| Kyowa Kirin, Inc. | 9 | $184 |
| Neurocrine Biosciences, Inc. | 8 | $166 |
| Biogen | 7 | $151 |
| Alnylam Pharmaceuticals Inc. | 7 | $129 |
| AstraZeneca(2 entities) | 7 | $126 |
| Genentech USA, Inc. | 1 | $125 |
| Amgen | 9 | $125 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $84 |
| GE HealthCare | 7 | $62 |
| Arbor Pharmaceuticals, Inc. | 2 | $62 |
| Biohaven Pharmaceuticals, Inc. | 4 | $54 |
| GSK | 3 | $52 |
| Boston Scientific | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Life Molecular Imaging Ltd | 2 | $35 |
| SK Life Science, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $24 |
| Abbott | 1 | $22 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $14 |
| Medtronic | 1 | $11 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,061 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 25 | $288 |
| ClopidogrelClopidogrel Bisulfate | 21 | $284 |
| Levetiracetam | 18 | $258 |
| Donepezil Hcl | 14 | $66 |
| Topiramate | 13 | $44 |
Paid to pharmacies, not to this prescriber.
Other neurology in Amherst
- Nicolas SaikaliAmherst$1.5M
- Jennifer McVigeAmherst$982K
- Bennett MyersAmherst$432K
- Laszlo MechtlerAmherst$347K
- Wisam ElmalikAmherst$289K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.